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Background: Biomarkers are needed to individualize cancer radiation treatment. Therefore, we have investigated
the association between various risk factors, including single nucleotide polymorphisms (SNPs) in candidate genes
and late complications to radiotherapy in our nasopharyngeal cancer patients.
Methods: A cohort of 155 patients was included. Normal tissue fibrosis was scored using RTOG/EORTC grading
system. A total of 45 SNPs in 11 candidate genes (ATM, XRCC1, XRCC3, XRCC4, XRCC5, PRKDC, LIG4, TP53, HDM2,
CDKN1A, TGFB1) were genotyped by direct genomic DNA sequencing. Patients with severe fibrosis (cases, G3-4,
n = 48) were compared to controls (G0-2, n = 107).
Results: Univariate analysis showed significant association (P < 0.05) with radiation complications for 6 SNPs
(ATM G/A rs1801516, HDM2 promoter T/G rs2279744 and T/A rs1196333, XRCC1 G/A rs25487, XRCC5 T/C rs1051677
and TGFB1 C/T rs1800469). In addition, Kaplan-Meier analyses have also highlighted significant association between
genotypes and length of patients’ follow-up after radiotherapy. Multivariate logistic regression has further sustained
these results suggesting predictive and prognostic roles of SNPs.
Conclusions: Univariate and multivariate analysis suggest that radiation toxicity in radiotherapy patients are
associated with certain SNPs, in genes including HDM2 promoter studied for the 1st time. These results support the
use of SNPs as genetic predictive markers for clinical radiosensitivity and evoke a prognostic role for length of
patients’ follow-up after radiotherapy.
Keywords: Single nucleotide polymorphism (SNP), Radiosensitivity, Late reactions to radiotherapy, Fibrosis, Follow
up, Nasopharyngeal carcinomaBackground
Genetic variations are frequent in humans, and the
challenge of radiogenomic studies is to determine which
polymorphisms influence individual radiosensitivity and
the risk to develop severe complications following radio-
therapy [1]. Single nucleotide polymorphism (SNP) is
the largest type of inherited genetic variation [2]. These
polymorphic variations can influence the stability of
mRNA, rate of transcription, the protein translation* Correspondence: galsbeih@kfshrc.edu.sa
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reproduction in any medium, provided the orand/or the protein-protein interactions leading to sub-
optimum function and expression of different degrees of
clinical radiation sensitivity [3]. To identify these varia-
tions, many investigators followed an intuitive approach
of targeting SNPs in candidate genes arbitrarily involved
in radiation response [4-6]. Although many studies,
carried out often on limited number of RT patients, have
reported significant associations, results were globally
inconsistent between studies [7].
The pathways involved in radiation response encompass
multitude of genes of which we have selected 11 candidate
genes for their presumed or demonstrated influence on
radiosensitivity [3,7-9]. These include CDKN1A (p21),
TP53, ATM, HDM2, TGFB1, XRCC1, XRCC3, XRCC4,
XRCC5 (Ku80), PRKDC, and LIG4 which are involved inLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to affect the outcome to radiation treatment [1], in this
study we have genotyped 45 (12 primary and 33 neigh-
boring) SNPs in 155 Head and Neck cancer patients
treated with curative radiotherapy, and have been asso-
ciated with follow-up and the grade of fibrosis in
normal tissues.
Methods
Patients’ population and clinical data
A total of 155 Head and Neck cancer patients had
consented to be enrolled in this study during treatment
or regular follow-up of their disease. The patients were
treated by standardized 3D conformal RT, before the
implementation of IMRT, for nasopharyngeal carcinoma
as described elsewhere [10,11]. Total radiation dose to the
upper neck was 66 Gy. Where possible, patients (n = 47)
received a boost of 2 additional fractions to the nasophar-
ynx to bring the dose received to 70 Gy. Locally advanced
stages (II to IVB, n = 74) received neoadjuvant and con-
current chemotherapy consisting of cisplatinum and
epirubicin [10]. The grade (G) of subcutaneous and deep
tissue fibrosis, a late radiation-induced complication, was
jointly evaluated by two participating physicians according
to the RTOG/EORTC grading system. The maximum
grade of fibrosis recorded over the length of the patients’
follow-up has been reported. For groups comparison,
patients with major toxicity [12], severe fibrosis (G3-4),
were referred to as the radiosensitive group (cases, n = 48)
and were compared to patients with minor (G0-2) fibrotic
reactions (controls, n = 107). The KFSHRC Research
Ethics Committee has approved the study (RAC # 2000
031 and 2040 025) and all patients had signed informed
consent.
DNA extraction, amplification, sequencing and
genotyping of polymorphisms
During the regular follow-up of the patients, a 5 ml blood
sample was drawn from consenting patients. DNA was
extracted using Puregene DNA Purification Kit (Gentra
System, USA) according to the manufacturer’s instruction.
The selected 12 primary SNPs were: CDKN1A (p21, Cip1)
codon 31 C/A (Ser/Arg) rs1801270, TP53 (p53) codon
72 G/C (Arg/Pro) rs1042522, HDM2 (MDM2) promoter
position 309 rs2279744, ATM codon 1853 G/A (Asp/Asn)
rs1801516, XRCC1 codon 399 G/A (Arg/Gln) rs25487,
XRCC3 codon 241 C/T (Thr/Met) rs861539, XRCC4
codon 247 G/T (Ala/Ser) rs3734091, XRCC5 (Ku80) 3′
UTR A/G rs1051685, LIG4 (DNA Ligase IV) codon 591
A/G (Ile/Val) rs2232641, LIG4 codon 9 C/T (Thr/lle)
rs1805388, PRKDC (DNA-PKcs) codon 3434 A/G (Ile/
Thr) rs7830743, TGFB1 (TGFß1) codon 10 C/T (Leu/Pro)
rs1982073. The PCR primers used are available upon
request. Relevant segments of DNA were amplified bythermal cycling, sequenced using the DYEnamic ET
Dye Terminator Cycle Sequencing Kit (Amersham
Biosciences) and genotyped using SeqManII sequence
analysis software (DNASTAR Inc.).Data analysis
The univariate analysis of the association between SNPs
allelic frequencies and grade of fibrosis were measured
by the odds ratio (OR) with its 95% confidence interval.
Significance of OR was assessed by the Chi-square (χ2)
test, continuity uncorrected. A P-value of 0.05 or less is
considered statistically significant. Kaplan-Meier analysis
was used to evaluate the potential relationship between
genotypes and length of patients follow-up. Multivariate
logistic regression was used to assess the joint effect of
all potential risk factors. Statistical analysis was carried
out using the IBM SPSS Statistics platform (Version 19,
SPSS Science, IL, USA).Results
Patients and treatment
The age of patients at RT ranged between 15 and
77 years/old with a median of 47. There were 39 females
and 116 males. All patients had completed at least
24 months of follow-up after RT (range: 24–180 months,
median: 40 months). Late normal tissue reactions to
radiotherapy (xerostomia, skin atrophy and subcutane-
ous and deep tissue fibrosis) were scored, however, only
grade of fibrosis is reported here because it was com-
pleted for all patients. There were 17, 54, 36, 38, and 10
patients who had exhibited fibrotic reactions of grade 0,
1, 2, 3 and 4, respectively.
Patients with major toxicity (G3 and G4, cases) were
compared to those having minor reactions (G0, G1 and
G2, controls) [12]. Therefore, radiosensitive patients
with severe subcutaneous and/or deep tissue fibrosis
(G3-4, cases, n = 48) were compared to patients having
no, mild or moderate fibrosis (G0-2, controls, n = 107).
The distribution of controls and radiosensitive patients
according to chemotherapy and radiation boost received
is given in Figure 1. Briefly, patients who received
chemotherapy (79) and RT boost (54) were proportion-
ally distributed between controls and cases. Thus, the
ratio of patients who received chemotherapy to the
patients who did not, were comparable in the control
and the radiosensitive groups (0.50 vs. 0.52, P = 0.80).
Similarly, the average total doses received (with and
without boost) in controls (67.50 Gy, SD = 1.94) and in
the radiosensitive groups (67.17 Gy, SD = 1.84) were not
significantly different (P = 0.35). Associated diseases were
uncommon (25 patients) who were proportionally dis-
tributed between cases and controls.
Figure 1 Distribution of the 155 nasopharyngeal carcinoma
patients according to the grade of subcutaneous and deep
tissue fibrosis following radiotherapy. The patients developed
either minimal to moderate (controls: G0-2) or severe (cases: G3-4)
fibrotic reactions. Patients who received chemotherapy (CT) or
radiotherapy boost (RT-B) are indicated.
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Between the 45 SNPs genotyped, 16 were all majority
(wild-types) alleles that have been omitted from the ana-
lysis. There were wide variations in the distribution of
the different genotypes according to the grade of
fibrosis. The allelic frequencies are given in Table 1. As
compared to the controls (G0-2), the radiosensitive
group (G3-4) harbored relatively higher number of vari-
ant ATM rs1801516 A allele which appeared to be a risk
factor (OR = 2.86, CI 95%: 1.18-6.48, P < 0.01), and lower
numbers of the variants HDM2 rs2279744 G (OR = 0.49,
CI 95%: 0.29-0.84, P < 0.01), the rare HDM2 rs1196333 A
(OR = 0.13, CI 95%: 0.02-0.99, P = 0.02), TGFB1 rs1800469
T (OR = 0.57, CI 95%: 0.34-0.96, P = 0.03), XRCC1 rs25487
A (OR = 0.41, CI 95%: 0.21-0.79, P < 0.01), and XRCC5
rs1051677C (OR = 0.39, CI 95%: 0.17-0.91, P = 0.02) alleles
which appeared to have protective effect; therefore, the
majority alleles were the risk factors. In addition, we have
computed the False Discovery Rate (FDR) for all P-values
of the SNPs tested. The FDR-values of the 6 significant
SNPs were between 0.14 and 0.009. This indicates that the
expected proportion of false positive discovery satisfies the
significance threshold allowed for this test (<0.20).
The relationship between the genotypes of the 6
significantly-associated-SNPs and the length of follow-
up following RT, a surrogate measure of patients’survival assuming that most absence to follow-up are
due to death, was evaluated using Kaplan-Meier analysis
(Figure 2). Results showed significant difference in the
median follow-up with respect to genotypes for ATM
rs1801516, HDM2 rs2279744 and XRCC1 rs25487 (Log
Rank Mantel-Cox test: P = 0.001, 0.03 and 0.04, respect-
ively). For these SNPs, the protective genotype, whether
majority or minority allele, correspond to longer
patients’ follow-up. Thus, the estimated medians follow-
up in months were: ATM rs1801516 A/A = 24, A/G = 80,
G/G = 114; HDM2 rs2279744 T/T = 75, T/G = 140, G/G =
114; XRCC1 rs25487 G/G = 79, G/A = 112, A/A = 180.
The joint effect of all potential risk factors (age,
gender, total radiation dose, chemotherapy, follow-up,
associated disease and genotypes), was assessed using
multivariate logistic regression (Table 2). Results showed
that HDM2 rs2279744, HDM2 rs1196333, TGFB1
rs1800469, XRCC1 rs25487 and Follow-Up (P = 0.03,
0.03, 0.007, 0.002 and 0.007, respectively) were signi-
ficantly associated with the group of fibrotic reaction
(G0-2 versus G3-4).
Discussion
The aim of this study was to evaluate in our local cancer
patients whether various risk factors including genetic
polymorphic variations in candidate genes involved in
radiation response are associated with the severity of
RT-induced fibrotic reactions in normal tissues. The 155
Head and Neck cancer patients included in this report
had nasopharyngeal carcinoma. This cancer site is preva-
lent in Saudi Arabia and is ideal for this type of study
because patients follow standardized treatment with
curative radiation without surgery [10]. This could be
considered contribution to the radiogenomic consortium
that contains mainly breast, prostate and gynecologic
cancer patients [13].
Among the 45 genetic variations scored, univariate
analysis showed significant association between grade of
fibrosis and allelic frequency of 6 SNPs (ATM rs1801516,
HDM2 rs2279744, HDM2 rs1196333, TGFB1 rs1800469,
XRCC1 rs25487 and XRCC5 rs1051677; Table 1) and
therefore, could be considered candidate for predictive
markers testing. These results were further sustained as
the values of the False Discovery Rate (FDR) of these SNPs
(0.14 - 0.009) have satisfied the significance threshold
allowed for this test (<0.20). Interestingly, apart from
ATM where the variant A allele was associated with
increased risk, the variant alleles of the remaining signifi-
cantly associated SNPs showed decreased risk (Odds or
Risk Ratios < 1) to develop severe fibrosis, and therefore,
they exhibit protective effect.
In addition, Kaplan-Meier analysis on these 6 SNPs
suggested that the protective alleles of 3 of these SNPs
(ATM rs1801516 A, HDM2 rs2279744 G, and XRCC1
Table 1 Allele frequencies of the assessed polymorphisms in 155 Head and Neck cancer patients who either developed
minimal (controls: G0-2) or severe (cases: G3-4) late reactions (fibrosis) after radiotherapy
Gene and SNP Allele 1a Allele 2b Odds ratio P-value
Cases Controls Cases Controls (95% CI)
n (%) n (%) n (%) n (%)
CDKN1A C/A rs1801270 74 (77) 157 (73) 22 (23) 57 (27) 0.82 (0.47–1.44) 0.49
TP53 G/C rs1042522 52 (54) 112 (52) 44 (46) 102 (48) 0.93 (0.57–1.51) 0.76
TP53 C/T rs1800371 96 (100) 213 (99.5) 0 (0) 1 (0.5) NI NI
ATM G/A rs1801516 82 (85) 202 (94) 14 (15) 12 (6) 2.86 (1.18–6.48) <0.01
HDM2 T/G rs2279744 71 (74) 125 (58) 25 (26) 89 (42) 0.49 (0.29–0.84) <0.01
HDM2 T/A rs1196333 95 (99) 198 (93) 1 (1) 16 (7) 0.13 (0.02–0.99) 0.02
TGFB1 G/A rs9282871 95 (99) 213 (99.5) 1 (1) 1 (0.5) NI NI
TGFB1 C/T rs1982073 40 (42) 102 (48) 56 (58) 112 (52) 1.28 (0.78–2.07) 0.32
TGFB1 G/C rs1800471 92 (96) 207 (97) 4 (4) 7 (3) NI NI
TGFB1 C/T rs1800469 67 (70) 122 (57) 29 (30) 92 (43) 0.57 (0.34–0.96) 0.03
TGFB1 G/A rs11466314 96 (100) 213 (99.5) 0 (0) 1 (0.5) NI NI
TGFB1 del rs8179182 94 (98) 214 (100) 2 (2) 0 (0) NI NI
TGFB1 C/T rs1800472 92 (96) 199 (93) 4 (4) 15 (7) 0.58 (0.19–1.79) 0.33
TGFB1 C/T rs11466334 95 (99) 213 (99.5) 1 (1) 1 (0.5) NI NI
XRCC1 G/A rs25487 83 (86) 155 (72) 13 (14) 59 (28) 0.41 (0.21–0.79) <0.01
XRCC1 C/T rs3213368 87 (91) 193 (90) 9 (9) 21 (10) 0.95 (0.42–2.16) 0.90
XRCC1 G/A rs2139720 88 (92) 190 (89) 8 (8) 24 (11) 0.72 (0.31–1.67) 0.44
XRCC1 C/T rs3213369 96 (100) 213 (99.5) 0 (0) 1 (0.5) NI NI
XRCC3 G/A rs861539 55 (57) 133 (62) 41 (43) 81 (38) 1.22 (0.75–1.99) 0.42
XRCC3 A/C rs3212112 95 (99) 213 (99.5) 1 (1) 1 (0.5) NI NI
XRCC4 G/T rs3734091 95 (99) 213 (99.5) 1 (1) 1 (0.5) NI NI
XRCC5 A/G rs41296835 96 (100) 213 (99.5) 0 (0) 1 (0.5) NI NI
XRCC5 T/C rs1051677 89 (93) 178 (83) 7 (7) 36 (17) 0.39 (0.17–0.91) 0.02
XRCC5 A/G rs1051685 85 (89) 195 (91) 11 (11) 19 (9) 1.33 (0.61–2.91) 0.48
PRKDC T/C rs7830743 93 (97) 197 (92) 3 (3) 17 (8) 0.37 (0.11–1.31) 0.11
LIG4 T/C rs1805384 90 (94) 200 (93) 6 (6) 14 (7) 0.95 (0.36–2.56) 0.92
LIG4 C/T rs4987182 93 (97) 209 (98) 3 (3) 5 (2) NI NI
LIG4 C/T rs1805389 95 (99) 206 (96) 1 (1) 8 (4) NI NI
LIG4 C/T rs1805388 91 (95) 195 (91) 5 (5) 19 (9) 0.56 (0.20–1.56) 0.26
Significantly associated SNPs are highlighted in bold.
a Allele 1: majority or wild-type allele. b Allele 2: minority or variant allele. NI: Not Informative because of low frequency.
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of patients. Our results suggest that on average, the
presence of protective allele at the heterozygous status
would increase patients’ follow-up by 51 months while
homozygous status would increase this index by
77 months. Thus, these SNPs could be used as prognos-
tic biomarkers for length of follow-up following radio-
therapy, as patients harboring protective alleles have
higher probability to live longer (Figure 2). Estimated
median follow-up suggests that harboring one protective
allele of each of these SNPs would increase survival by
about 4 years, while having the 2nd protective allele
would add 2 more years.Multivariate logistic regression, that assesses the joint
effect of various risk factors, has confirmed the association
between HDM2 T/G rs2279744, HDM2 T/A rs1196333,
TGFB1 C/T rs1800469, XRCC1 G/A rs25487, follow-up
and radiosensitivity (Table 2). These are interesting results
that plaid in favor of the potential use of genetic markers
as predictors of normal tissue response and prognostic of
follow-up. This is an important conclusion since the
subject is currently a hot topic debate [7]. For instance, a
large prospective study has failed to replicate previously
reported associations between individual SNP genotype
and radiation toxicity [7]. On the contrary, genome-wide
associations study evaluating erectile dysfunction
Figure 2 Kaplan-Meier analysis of the relationship between the genotypes of the 6 significantly-associated-SNPs and length of
patients’ follow-up following radiotherapy. Symbols represent censored data points.
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ation not only in a gene that plays a role in male gonad
function, but also in genes that relate to specific
African ancestry [14].
This is the first study on the association between HDM2
T309G promoter (rs2279744) and radiosensitivity; previous
studies were only concerned with its cancer predisposing
potential [15]. The functional polymorphic variant in the
HDM2 promoter at position 309 (rs2279744) have been
suggested to affect the transcriptional activator SP1 bind-
ing, thereby modulating HDM2 transcription level. The G
variant has been shown to increase the affinity for Sp1,
resulting in higher levels of HDM2 mRNA and proteinTable 2 Multivariate logistic regression analysis of
various risk factors that might affect patients’ risk to
develop severe fibrosis following radiotherapy
Risk factors P value
ATM G/A rs1801516 0.55
HDM2 T/G rs2279744 0.03
HDM2 T/A rs1196333 0.03
TGFB1 C/T rs1800469 <0.01
XRCC1 G/A rs25487 <0.01
XRCC5 (Ku80) T/C rs1051677 0.42
Gender 0.79
Age at Radiotherapy 0.56




Significant associations are highlighted in bold.and the subsequent attenuation of the TP53 pathway [16].
Results presented here showed that the same variant G
allele, and also the variant G allele in the neighboring
HDM2 rs2279744 SNP, is associated with reduced risk to
develop late normal tissues complications, a phenomenon
that is dependent on the amount of cell depletion follo-
wing radiotherapy. Therefore, in line with our results, it is
conceivable that this HDM2 G variant allele could pro-
mote cell survival following irradiation and thus, cells
would appear more radioresistant, despite the probable
high risk of genomic instability due to presumably atte-
nuated TP53. This may also have implication for the
promotion of secondary cancers following radiotherapy.
In addition, this is also the 1st study to report asso-
ciation between XRCC5 (KU80) polymorphisms and
clinical radiosensitivity. XRCC5 is a component of the
non-homologous end-joining (NHEJ) to repair DNA
double-strand breaks. Previously, SNPs in XRCC5 have
been shown to influence cancer risk and chromosomal
radiosensitivity [15]. Our study showed that, although
uncommon, the variant XRCC5 rs1051677 C allele was
more frequent in the controls, thus it has a protective
effect. The variant ATM rs1801516 A allele (Asn) was
previously reported to be significantly associated with
increased radiation sensitivity [17]. Other studies have
also showed similar association with enhanced risk of
various adverse reactions after RT [18]. On the other
hand, the majority XRCC1 rs25487 allele (Arg) was asso-
ciated with increased risk to develop late reactions to
radiotherapy (Reviewed in [19]). This suggests that the
variant (or minority) allele could confer higher radio-
resistance in favor of normal tissues involved in the
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cytokine TGFB1 assumed to be involved in response to
tissue injuries. Therefore, SNPs that alter protein pro-
duction can results in excessive deposition of scar tissue
and fibrosis. Therefore, many SNPs have been studied in
the literature and the effect of haplotype needs to be
clarified as co-segregation of polymorphic variations in
TGFB1 gene has been suggested to play a role in
radiation response [3,5,20].
Results presented here are encouraging and illustrates
that radiation response requires the concerted action of
multiple genes and, therefore, it is a complex genetically
controlled trait with the outcome being determined by
multitude of additive effects. In addition, the original
demonstration of an association between certain SNPs
and length of followup after radiotherapy suggests
prognostic role for patients’ survival. The results also
indicate that not all variant SNPs are risky, and some of
them could be advantageous from a radiosensitivity
point of view. The SNPs studied were synonymous, non-
synonymous and in non-coding regions of the genome.
From an evolutionary perspective, the genome is in con-
sistent development due to environmental interactions
and, in general, natural selection favors the allele of the
SNP that constitutes the most advantageous genetic
adaptation. It is possible that the substitutions observed
frequently are likely to be neutral or favorable, whereas
those observed rarely are likely to be deleterious [21].
Although a large prospective study has failed to replicate
previously reported associations between individual
SNPs genotype and radiation toxicity [7], a genome-wide
associations study evaluating erectile dysfunction follow-
ing radiotherapy for prostate cancer has showed signifi-
cant association not only in a gene that plays a role in
male gonad development and function, but also in genes
that relate to specific African ancestry that would not
have been identified in a cohort of European ancestry
[14]. The genomic revolution with the advent of high-
throughput techniques can help uncovering the panoply
of these interacting factors at the DNA (genome), RNA
(transcriptome) or protein (proteome) level. Research
using genome-wide analysis tools heralds the future of
individualized radiation treatment in broadly personal-
ized medicine. In addition to predictive and prognostic
testing, the products of the identified genes could be-
come targets for innovative therapies in susceptible
individuals.
Conclusions
Univariate analysis showed that between 45 SNPs in 11
genes involved in cell cycle control and DNA repair, 6
were significantly associated with radiation toxicity in
radiotherapy patients. Kaplan-Maier analysis has high-
lighted a significant association between genotype andfollow-up of patients. Multivariate logistic analysis has
sustained these conclusions. Larger cohort, independent
replication of these findings and genome wide association
studies (GWAS) are required to confirm these results and
validates the use of SNPs as predictive and prognostic
biomarkers to individualize radiotherapy on genetic basis.
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